Sugi Predict

Sugi Predict / Compounds / SCHEMBL1055676

SCHEMBL1055676

SCHEMBL1055676

CC(C)(C)OC(=O)n1cc(Br)c2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ MARK3 P27448 1/20 0.47
▸ MAP4K2 Q12851 1/20 0.47
▸ CAMK2B Q13554 1/20 0.47
▸ PIM3 Q86V86 1/20 0.47
▸ PIM2 Q9P1W9 1/20 0.47
▸ EPHX1 P07099 1/20 0.47
▸ ACHE P22303 1/20 0.45
▸ BRD4 O60885 1/20 0.45
▸ CREBBP Q92793 1/20 0.45
▸ HTR6 P50406 2/20 0.43
▸ BCHE P06276 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM4 P08173 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ CHRM3 P20309 1/20 0.43
▸ PDE10A Q9Y233 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374710 1.00 L3MBTL1 (0.57) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL2111547 0.84 L3MBTL1 (0.48) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL25358569 0.84 HTR6 (0.61) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL1196430 0.83 L3MBTL1 (0.59) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL21259294 0.83 L3MBTL1 (0.59) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL1196432 0.83 L3MBTL1 (0.62) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL21246906 0.83 L3MBTL1 (0.59) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL21919934 0.83 GABRG2 (0.48) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL25244266 0.83 HTR6 (0.46) L3MBTL1MEN1KMT2APIM1MARK3
SCHEMBL3051164 0.83 HTR6 (0.46) L3MBTL1MEN1KMT2APIM1MARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421191-B2 3-hydroxyoxindole derivatives as CRHR2 antagonist RAQUALIA PHARMA INC. (JP) 2025-09-23 — — US disclosed
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2025-06-05 — — US disclosed
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds ZOETIS SERVICES LLC (US) 2025-03-04 — — US disclosed
CN-118184567-B Process for preparing 3-haloindole derivatives 常州工程职业技术学院 2025-02-18 — — CN disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 — — US disclosed
CN-115010726-B Cage compound, intermediate thereof, preparation method and application thereof 中国科学院上海有机化学研究所 2024-08-16 — — CN disclosed
EP-3947360-B1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC (US) 2024-08-07 — — EP disclosed
US-20240254081-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS KARE CHEMICAL TECHNOLOGIES INC. (CA) 2024-08-01 — — US disclosed
CN-118184567-A Process for preparing 3-haloindole derivatives 常州工程职业技术学院 2024-06-14 — — CN disclosed
EP-4334285-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS Kare Chemical Technologies Inc. (CA) 2024-03-13 — — EP disclosed
EP-2102229-A1 PYRROLYDINE DERIVATIVES AS IAP INHIBITORS Novartis AG (CH) 2009-09-23 — — EP disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 — — EP disclosed
WO-2008045905-A1 PYRROLYDINE DERIVATIVES AS IAP INHIBITORS NOVARTIS AG (CH) 2008-04-17 — — WO disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 — — WO disclosed
US-5382670-A Platelet activating factor antagonists ABBOTT LABORATORIES (US) 1995-01-17 — — US disclosed
EP-0574494-A4 INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LAB (US) 1994-07-06 — — EP disclosed
EP-0574494-A1 INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1993-12-22 — — EP disclosed
WO-1992014732-A1 INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1992-09-03 — — WO disclosed
EP-0499987-A1 Platelet activating factor antagonists ABBOTT LABORATORIES (US) 1992-08-26 — — EP disclosed
US-5120749-A Treatment of anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellulosr immunity, parturtition, fetal lung maturation, and cellular differentiation ABBOTT LABORATORIES (US) 1992-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds HTR2B, HTR1B, HTR5A L3MBTL1 2907/4885MEN1 240/4885KMT2A 2893/4885
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR5A L3MBTL1 2907/4885MEN1 240/4885KMT2A 2893/4885
US-20240254081-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS HNMT, TPSB2, TPSG1 L3MBTL1 4653/4885MEN1 379/4885KMT2A 390/4885
US-12421191-B2 3-hydroxyoxindole derivatives as CRHR2 antagonist CRHR2, CRHR1, CRH L3MBTL1 3814/4885MEN1 1996/4885KMT2A 4117/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 L3MBTL1 1869/4885MEN1 4354/4885KMT2A 3415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.